Back to results
US 8,012,465 B2Granted
Methods for treating renal cell carcinoma
AssigneeNovartis Vaccines and Diagnostics, Inc.
InventorsLaurence Elias, Gary Witherell
Life of this patent
Estimating the term…
Abstract
Methods for treating renal cell carcinoma using low doses of IL-2 are disclosed. In particular, the invention relates to methods of treating metastatic renal cell carcinoma in patients who are renally impaired and/or intolerant of high dose IL-2 therapy. The therapeutic regimen described herein significantly inhibits tumor growth with reduced toxicity and adverse side effects compared to high dose IL-2 therapy.
Claims18
A method for treating a human patient having renal cell carcinoma, the method comprising:
- a) first, administering a dose of 18 MIU of an IL-2 mutein per day for 5 days during one week;
- b) second, administering a dose of 9 MIU of the IL-2 mutein per day for 2 days followed by administering a dose of 18 MIU of the IL-2 mutein per day for 3 days during each week, repeated for 5 weeks;
- c) third, administering no IL-2 mutein for 3 weeks;
- d) fourth, administering a dose of 9 MIU of the IL-2 mutein per day for 5 days of each week, repeated for 6 weeks;
- and
- e) fifth, administering no IL-2 mutein for 3 weeks,
- wherein said IL-2 mutein is administered by subcutaneous, intraperitoneal, intramuscular, intravenous, oral, pulmonary, nasal, topical, or transdermal administration, or by infusion or suppositories.
4 more elements
Dependencies are inferred from the claim text.